Legend Biotech (LEGN) Current Deferred Revenue (2019 - 2026)
Legend Biotech's (LEGN) quarterly Current Deferred Revenue came in at $6.0 million in Q1 2026, down 84.82% YoY from $39.5 million in Q1 2025, and down 46.9% on a QoQ basis from $11.3 million in Q4 2025.
Legend Biotech (LEGN) Current Deferred Revenue (2019 - 2026) Analysis & Trends
Legend Biotech (LEGN) has 8 years of Current Deferred Revenue data on file, last reported at $6.0 million in Q1 2026.
- Quarterly Current Deferred Revenue fell 84.82% year-over-year to $6.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $6.0 million (down 84.82% YoY) and the FY2025 annual result came in at $11.3 million, down 75.91% from the prior year.
- Current Deferred Revenue slipped to $6.0 million in Q1 2026, from $11.3 million in the prior quarter.
- In the past five years, Current Deferred Revenue ranged from a high of $245.8 million in Q1 2022 to a low of $6.0 million in Q1 2026.
- A 5-year average of $63.4 million and a median of $50.0 million in 2023 frame the typical range for Current Deferred Revenue.
- Annual changes were most pronounced in 2022 — Current Deferred Revenue soared 94945.35% — and 2026, when it tumbled 84.82%.
- Tracing LEGN's Current Deferred Revenue over 5 years: stood at $245.8 million in 2022, then plunged by 78.44% to $53.0 million in 2023, then retreated by 11.53% to $46.9 million in 2024, then sank by 75.91% to $11.3 million in 2025, then slumped by 46.9% to $6.0 million in 2026.
- The last three Current Deferred Revenue figures came in at $6.0 million (Q1 2026), $11.3 million (Q4 2025), and $22.6 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Legend Biotech | 3.95 Bn | 3.27 Bn | 251.50 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 700,000.00 |
| Mar 31, 2026 | 6.00 Mn |
| Dec 31, 2025 | 11.30 Mn |
| Sep 30, 2025 | 22.58 Mn |
| Jun 30, 2025 | 33.18 Mn |
| Mar 31, 2025 | 39.54 Mn |
| Dec 31, 2024 | 46.90 Mn |
| Sep 30, 2024 | 63.16 Mn |
| Jun 30, 2024 | 74.85 Mn |
| Mar 31, 2024 | 63.25 Mn |
| Dec 31, 2023 | 53.01 Mn |
| Mar 31, 2023 | 100.97 Mn |
| Mar 31, 2022 | 245.85 Mn |
| Dec 31, 2021 | 60.64 Mn |
| Sep 30, 2021 | 237.22 Mn |
| Jun 30, 2021 | 252,628.00 |
| Mar 31, 2021 | 258,666.00 |
| Dec 31, 2020 | 55.01 Mn |
| Sep 30, 2020 | 245,641.00 |
| Jun 30, 2020 | 254,714.00 |